Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets

Journal of Gastrointestinal Surgery

Volumn 19, Issue 10, 2015, Pages 1802-1812

  Casadei, Riccardo ^a   Di Marco, Mariacristina ^a   Ricci, Claudio ^a   Santini, Donatella ^a   Serra, Carla ^a   Calculli, Lucia ^a   D’Ambra, Marielda ^a   Guido, Alessandra ^a   Morselli Labate, Antonio Maria ^a   Minni, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemoradiotherapy; Pancreatic cancer; Pancreatic resection

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; AGED; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; HUMAN; ITALY; MALE; MIDDLE AGED; MORTALITY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84942501370     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-2890-4     Document Type: Article

References (39)

1. Gooiker GA, vanGijn W, Wouters MWJM, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011;98:485–494.
2. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385–387.
3. Richter A, Niedergetnmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25 years experience. World J Surg 2003;27:324–329.
4. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
5. Klinkenbijl JH, Jeekel J, Sahmond T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–782.
6. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001;358:1576–1585.
7. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of rancreatic cancer. A Randomized Controlled Trial. JAMA 2007;297:267–277.
9. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019–1026.
10. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073–1081.
11. Brunner TB. Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm? Curr Oncol Rep 2013;15:162–169.
12. Wayne JD, Abdalla EK, Wolff RA et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002;7:34–45.
13. Spitz FR, Abruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928–937.
14. Mornex F, Girard N, Delpero J et al. Radiochemotherapy in the management of pancreatic cancer—part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226–234.
15. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.
16. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121–130.
17. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
18. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011;150:466–473.
19. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a mata-analysis of prospective studies. Ann Surg Oncol 2012;19:1644–1662
20. Xu CP, Xue XJ, Liang N, et al. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014;140:549–559.
21. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer. Results of the first prospective randomized phase II trial. Strahlenther Onkol 2014; DOI 10.1007/s00066-014-0737-7.
22. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes and prognostic indicators. J Gastrointest Surg 2000;4:567–579.
23. Takai S, Satoi S, Toyokawa H, et al. Clinicopathological evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003;26:243–249.
24. Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 1992;215:231–236.
25. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
26. Le Scodan R, Mornex F, Partensky C, et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma. The French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol 2008;31: 545–552.
27. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232–1237.
28. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000;92:205–216.
30. White RR, Xie HB, Gottfried MR et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer tumor. Ann Surg Oncol 2005;12:214–221.
31. Lüttges J, Zamboni G and Klöppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. Dig Surg 1999;16:291–296.
32. Exocrine pancreas in Greene FL, Page DL, Fleming ID et al. (eds): AJCC Cancer Staging Manual (Ed.6). New York, Springer, 2002, pp157-164.
33. Dindo D, Demartines N, Clavien PA. Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
34. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.
35. Wente MN, Veit JA, Bassi C et al. Postpancreatectomy haemorrhage (PPH)—an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142:20–25.
36. Koch M, Garden OJ, Padbury R, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011;149:680–688.
37. Winter JM, Cameron JL, Campbell KA et al. 1423 Pancreaticuodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199–1211
38. van Geenen RC, van Gulik TM, Offerhaus GJ et al. Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol. 2001;27:549–57
39. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ 2010;340:c332.